Gabapentin Monotherapy for the Treatment of Chemotherapy-Induced Neuropathic Pain: A Pilot Study

Tsavaris, Nicolas; Kopterides, Petros; Kosmas, Christos; Efthymiou, Athina; Skopelitis, Hlias; Dimitrakopoulos, Antonios; Pagouni, Eyterpi; Pikazis, Dimitrios; Zis, P.V; Koufos, Christos

doi:10.1111/j.1526-4637.2007.00325.x

Cited by 58 publications

(48 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonhematologic toxicity such as peripheral neurotoxicity was manageable with symptomatic treatment and reversible in all cases. Patients received gabapentin monotherapy for the management of chemotherapy-induced neuropathic pain which has been shown to be useful in the treatment of such patients [15]. Furthermore, vomiting never caused therapy interruption (table 2).…”

Section: Resultsmentioning

confidence: 99%

Cisplatin and Vinorelbine Chemotherapy in Recurrent Vulvar Carcinoma

et al. 2009

View full text Add to dashboard Cite

Purpose: To evaluate the activity and toxicity of the combination of cisplatin and vinorelbine in patients with recurrent carcinoma of the vulva that has not been previously treated with chemotherapy. Patients and Methods: Sixteen women with a median age of 65 years (range 43–79) with recurrent vulvar carcinoma were enrolled in the study. Nine patients had local recurrent disease (perineum, vagina and/or vulva), whereas 7 had disease in the groin; 9 patients had received prior radiotherapy. Cisplatin was administered intravenously on day 1 and vinorelbine was given on day 1 immediately after cisplatin and on day 8. Results: A total of 68 cycles of chemotherapy were administered. Fifteen women were assessed for response. Objective responses were recorded in 6 patients (40%) – with 4 patients (27%) achieving a complete response and 2 (13%) achieving a partial response –, whereas 4 patients (27%) had stable disease and 5 had progressive disease. The median progression-free survival was 10 months (range 3–17), whereas the overall survival from the beginning of the chemotherapy was 19 months (range 1–30). Due to the small number of patients, no significant correlation with site of recurrence could be found. Conclusion: The combination of cisplatin and vinorelbine is a well-tolerated and active regimen in the treatment of patients with recurrent vulvar carcinoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Cisplatin and Vinorelbine Chemotherapy in Recurrent Vulvar Carcinoma

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In the control group, none experienced complete response, while partial, minor, and no response were observed in 5.7%, 45.7%, and 48.6%, respectively. 182 Gabapentin has also been studied in a multicenter, randomized, double-blind, placebo-controlled trial, including 121 cancer patients with NCP. Patients had ineffective analgesia with opioids and they were started on gabapentin at a dose of 600 to 1800 mg/day.…”

Section: 155mentioning

confidence: 99%

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

et al. 2011

View full text Add to dashboard Cite

Neuropathic cancer pain (NCP), commonly encountered in clinical practice, may be cancer-related, namely resulting from nervous system tumor invasion, surgical nerve damage during tumor removal, radiation-induced nerve damage and chemotherapy-related neuropathy, or may be of benign origin, unrelated to cancer. A neuropathic component is evident in about 1/3 of cancer pain cases.Although from a pathophysiological perspective NCP may differ from chronic neuropathic pain (NP), such as noncancer-related pain, clinical practice, and limited publications have shown that these two pain entities may share some treatment modalities. For example, co-analgesics have been well integrated into cancer pain-management strategies and are often used as First-Line options for the treatment of NCP. These drugs, including antidepressants and anticonvulsants, are recommended by evidence-based guidelines, whereas, others such as lidocaine patch 5%, are supported by randomized, controlled, clinical data and are included in guidelines for restricted conditions treatment. The vast majority of these drugs have already been proven useful in the management of benign NP syndromes. Treatment decisions for patients with NP can be difficult. The intrinsic difficulties in performing randomized controlled trials in cancer pain have traditionally justified the acceptance of drugs already known to be effective in benign NP for the management of malignant NP, despite the lack of relevant high quality data. Interest in NCP mechanisms and pharmacotherapy has increased, resulting in significant mechanism-based treatment advances for the future. In this comprehensive review, we present the latest knowledge regarding NCP pharmacological management. n INTRODUCTIONFollowing EFIC's (European Federation of IASP Chapters) declaration in 2001, pain is not a symptom but a disease in its own right, necessitating appropriate treatment. The word pain usually refers to a discrete sensory experience, triggered by an identifiable set of ''painful'' stimuli, acting on a unique or stable ''pain'' pathway and eliciting an invariant sensation. However, pain, and particularly neuropathic pain (NP) can also exist as a diverse group of complex phenomena of unpleasant and distressing nature. NP encloses numerous complicated neurobiologic constituents and reflects potentially dynamic mechanisms, interacting at multiple neuraxial sites. 1Modern neurobiological techniques have led to tremendous progress in the exploration of pain pathogenetic mechanisms. [2][3][4] Research indicates that pain can be produced in multiple ways, at different locations, co-existing between and across various pathological conditions. 5,6 Novel therapeutic targets have been discovered and are used by the pharmaceutical industry for the construction of highly specific molecules, acting as potential innovative analgesics. Recent targets' application, specific to precise NP mechanisms, will very soon enable treatment to be focused at particular mechanisms, introducing a mechanism-based therap...

show abstract

“…Despite previous reports showing an opioid to effectively relieve PN (Gatti et al, 2009;Watson et al, 2003), the lack of co-administration of opioids was not identified as a predictor for CIPN (Kanbayashi et al, 2010). Further research is warranted in regard to the potential prophylactic effects of agents such as steroids, NSAIDs (particularly COX2-specific NSAIDs), gabapentinoids (gabapentin or pregabalin) and opioids on the development of CIPN (Attal et al, 2006;Rao et al, 2007;Tsavaris et al, 2008;Vanotti et al, 2007;Vondracek et al,2009). Risk factors for CIPN such as gene polymorphism have already been reported, but the interrelationship of CIPN and gene polymorphism in particular will need to be verified at a later date.…”

Section: Resultsmentioning

confidence: 68%